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Background: Limited large-scale studies have been conducted to investigate the adverse effects of COVID-19
vaccine in Latin America, particularly among the healthcare worker (HCW) population in Ecuador. The objec
tive of this study was to assess a cohort of Ecuadorian healthcare workers for adverse reactions following
vaccination with the Pfizer-BioNTech vaccine.
Methods: We conducted an observational cross-sectional study to assess the potential adverse reactions to the
Pfizer-BioNTech COVID-19 vaccine among a sample of healthcare workers (HCWs) in the city of Guayaquil,
Ecuador, from March to May 2021.
Results: The sample comprised 1291 patients, with a mean age of 39.3 years (SD, 13.5). In general, 79% (N =
1020) of participants presented an adverse effect of any type at first dose, while 75.1% (N = 969) did so at the
second dose. Pain at the puncture site was the most common adverse effect overall after either the first (68.4%)
and second (55.6%) dose. Regarding anaphylaxis, no participant developed the condition after the first dose, and
only 0.2% (N = 2) developing it at the second dose. No fatalities were reported.
Conclusion: Our findings suggest that adverse reactions following COVID-19 vaccination with the PfizerBioNTech vaccine are relatively common, albeit often mild and self-limited. Consistent with the literature
there were few cases of anaphylaxis, and no deaths that could be attributed to the inoculation with the vaccine.
We hope our findings can help to reassure the public that benefits of vaccination highly outweigh the risks and
contribute to the effort of reducing vaccine hesitancy among those who are concerned about the safety and
potential side effects.

1. Introduction
The COVID-19 pandemic bears a burden on medical care and econ
omies worldwide, however immunization at the population level pro
vides a way for to reduce future morbidity and mortality [1]. Vaccine
hesitancy and reluctance in getting the COVID-19 vaccine and appre
hensions about them have been present along the course of vaccination

programs and mass immunizations across the world [2]. Factors such as
the quick, large-scale production of vaccines, lack of information, and
uncertainty about adverse reactions in the public’s eye as well about
myths spreading through media channels have given rise to suspicion
and fear in the Latin American population [2]. Limited large-scale
studies have been conducted to investigate the adverse effects of
COVID-19 vaccine in Latin America, particularly among the healthcare
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worker (HCW) population in Ecuador. The objective of this study was to
assess a cohort of Ecuadorian healthcare workers for adverse reactions
following vaccination with the Pfizer-BioNTech vaccine.

Table 2
Mean age and time between outcomes of interest.

2. Methods
We conducted an observational cross-sectional study to assess the
potential adverse reactions to the Pfizer-BioNTech COVID-19 vaccine
among a sample of healthcare workers (HCWs) in the city of Guayaquil,
Ecuador, from March to May 2021. All individuals involved were part of
the first phase of the national COVID-19 vaccination plan in our country
and were contacted through a local registry established by a local pri
vate university. In the first telephone call, potential participants were
explained about the purpose of the study, and only after voluntary
informed consent was obtained further information was collected.
Thereafter, weekly telephone calls were set up to ascertain if adverse
reactions had occurred within 14 days of receiving the vaccine.
This study was conducted according to the principles established by
the Declaration of Helsinki and was approved by the Expedited Ethics
Committee of the Ecuadorian Health Ministry (Approval N◦ 024–2020).
With the information recollected in the survey, personal identification
was not possible; as such, anonymity, and personal data protection was
guaranteed.

Age
Days between vaccine doses
Time to present adverse effect after first dosea
Time for local adverse effecta
Time for systemic adverse effecta
Time to present adverse effect after second dosea
Time for local adverse effecta
Time for systemic adverse effecta
Days presenting adverse effect after onset (first dose)
Days for local adverse effect
Days for systemic adverse effect
Days presenting adverse effect after onset (second dose)
Days for local adverse effect
Days for systemic adverse effect

39.3 (13.5)
21.5 (1.47)
6.6 (6.5)
7.2 (6.6)
6.9 (6.5)
6.1 (5.4)
6.5 (5.5)
7.2 (6.2)
2.6 (1.7)
2.4 (1.6)
2.1 (1.5)
2.4 (1.7)
2.3 (1.5)
0.5 (0.4)

received one dose. The average time between the first and the second
dose was 21.5 days (SD, 1.47).
In general, 79% (N = 1020) of participants presented an adverse
effect of any type at first dose, while 75.1% (N = 969) did so at the
second dose (Table 3). Local adverse effects were more common than
systemic adverse effects at first (69.4% and 43.1%, respectively) and
second (58.3% and 51.6%, respectively) doses. Pain at the puncture site
was the most common adverse effect overall after either the first

The sample comprised 1291 patients with a gender distribution of
50.4% female and 41.6% male patients. The mean age of the sample was
39.3 years (SD, 13.5) years (Tables 1 and 2). Around a quarter of the
sample had at least one comorbidity (23.3%) and a past medical history
compatible with allergic disease (23.1%), where arterial hypertension
(11.5%) and drug allergy (10.1%) were reported as the most common
conditions, respectively. Furthermore, 28.1% of the studied sample
confirmed to be infected with COVID-19 in the past, at least once, no
more than a month prior to vaccination. Regarding the vaccine regimen,
73.1% had completed a double dose standard, while 26.9% had only

Table 3
Adverse effects frequencies at first and second doses.

Table 1
Demographic and clinical information of surveyed population (n =
1291).
Gender
Male
Female
Comorbidity
Arterial hypertension
Diabetes
Hypothyroidism
Other
History of allergic condition
Drug allergy
Allergic rhinitis
Food allergy
Asthma
Atopic dermatitis
Past COVID-19 infection
Vaccine doses received
Single dose
Double dose
Outpatient self-medicated
FG-Anti-H1
Acetaminophen
Antibiotics
Medical attention
FG-Anti-H1
Acetaminophen
Other NSAIDs

Mean (SD)

Notes:
a
Time is in hours.

3. Results

Characteristics

Adverse effect

Value % (N)
41.6 (537)
58.4 (754)
23.3 (301)
11.5 (149)
3.6 (47)
2.2 (29)
6.1 (79)
23.1 (298)
10.1 (131)
8.8 (113)
5.1 (66)
3.6 (47)
1.5 (19)
28.1 (363)
26.9 (347)
73.1 (944)
4.4 (57)
4.3 (55)
0.1 (1)
0.1 (1)
1.5 (19)
0.5 (7)
34.2 (442)
3.5 (45)

Notes: FG-Anti-H1, First generation antihistamine H1 receptor;
NSAIDs, Nonsteroidal anti-inflammatory drugs.
2

Characteristics

First dose Value % (N)

Second dose Value % (N)

Adverse effect
Local adverse effect
Pain
Erythema
Edema
Pruritus
Axillary edema
Systemic adverse effect
Fever
Cephalea
Malaise
Myalgia
Arthralgia
Nausea/Vomiting
Diarrhea
Chills
Fatigue
Somnolence
Syncope
Paresthesia
Anxiety
Dizziness
Epigastric pain
Generalized rash
Generalized pruritus
Allergic rhinitis
Petechiae
Throat itchiness
Allergic sinusitis
Facial edema
Bronchospasm
Allergic conjunctivitis
Dermatitis
Ezcema
Ocular edema
Idiopathic urticaria
Lip swelling
Tongue swelling
Lip itchiness
Facial rash
Anaphylaxis

79.0 (1020)
69.4 (896)
68.4 (883)
5.5 (71)
8.0 (103)
0.6 (8)
1.6 (21)
43.1 (557)
11.5 (149)
18.1 (234)
19.8 (255)
4.6 (60)
4.4 (5)
2.7 (35)
2.9 (37)
3.5 (45)
6.0 (78)
2.6 (34)
0.1 (1)
1.0 (13)
0.4 (5)
2.7 (35)
1.3 (17)
0.8 (10)
0.6 (8)
0.2 (3)
0.2 (3)
0.6 (8)
0.4 (5)
0.1 (1)
0.1 (1)
0.1 (1)
0.0 (0)
0.1 (1)
0.0 (0)
0.1 (1)
0.1 (1)
0.1 (1)
0.0 (0)
0.1 (1)
0.0 (0)

75.1 (969)
58.3 (753)
55.6 (718)
10.8 (139)
12.8 (165)
1.2 (16)
1.1 (14)
51.6 (666)
18.0 (233)
23.8 (307)
28.0 (362)
6.3 (81)
8.4 (109)
2.9 (38)
2.3 (30)
6.3 (81)
5.4 (70)
2.3 (30)
0.0 (0)
1.2 (15)
0.7 (9)
2.2 (29)
0.5 (7)
0.3 (4)
06 (8)
0.5 (7)
0.3 (4)
0.2 (2)
0.1 (1)
0.0 (0)
0.0 (0)
0.1 (1)
0.1 (1)
0.2 (2)
0.1 (1)
0.0 (0)
0.2 (2)
0.0 (0)
0.1 (1)
0.0 (0)
0.2 (2)
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(68.4%) and second (55.6%) dose. In sequence, malaise was the second
most common adverse effect overall. Other local adverse effects that
were relatively frequent were edema and erythema, whereas headache
and fever were notable systemic adverse effects observed after either
vaccine dose administration. Regarding anaphylaxis, no participant
developed the condition after the first dose, and only 0.2% (N = 2)
developing it at the second dose. No fatalities were reported.
Overall, 79% of the HCWs had an adverse event on the first dose,
whereas 75.1% did with the second dose. The local adverse events were
more common with the first dose (69.4%) whereas systemic adverse
effects were more common with the second dose. As with the CDC
report, pain was the most common overall adverse effect. Anaphylaxis
was observed in only 2 HCWs post the second dose with no deaths
reported.

vaccine hesitancy among those who are concerned about the safety and
potential side effects.
In light of our findings, there are several limitations worth
mentioning. Our sample consisted of healthcare workers who had been
informed about the study’s purpose before participating, which may
have affected their perception of adverse effects. Also, participants were
asked to identify past adverse events, so recall bias might have been
present. However, to our knowledge this study is among the first to
report the occurrence of adverse reactions related to COVID-19 in an
Ecuadorian population.
5. Conclusions
Our findings suggest that adverse reactions following COVID-19
vaccination with the Pfizer-BioNTech vaccine are relatively common,
albeit often mild and self-limited. Local reactions such as pain in the
injection site account for the majority of events, while systemic/severe
reactions are rare. Consistent with the literature there were few cases of
anaphylaxis, and no deaths that could be attributed to the inoculation
with the vaccine. We hope our findings can help to reassure the public
that benefits of vaccination highly outweigh the risks and contribute to
the effort of reducing vaccine hesitancy among those who are concerned
about the safety and potential side effects.

4. Discussion
The centers for disease control and prevention (CDC) finds that
among an intervention (N = 2291) and placebo group (N = 2298),
84.7% vaccine recipients reported at least one local injection site reac
tion [3]. The most frequent local reaction was pain at the injection site.
As compared to pain, swelling and redness following either dose of the
Pfizer-BioNTech vaccine were less frequently reported [3]. Consistent
with previous reports, we found that local adverse reactions were more
common than systemic adverse reactions, with pain at the puncture site
the most commonly reported event at both doses. It is worth noting that
most of the observed reactions were mild or moderate in severity, which
coincides with the reports on vaccine safety [1].
On the other hand, serious adverse events are defined as any unto
ward medical occurrence that results in death, is life threatening, and
that requires hospitalization, possibly leading to persistent disability.
The percentage of serious adverse events in the vaccine (0.6%) and
placebo group (0.5%) have been somewhat similar, with two events
namely shoulder injury and lymphadenopathy documented by the FDA
post vaccination [3]. Overall, the FDA and CDC reports state that the risk
of serious adverse events that involve organ classes are balanced be
tween placebo and vaccine groups. Our study results are consistent with
reported literature, as we found no cases of serious adverse events
related to the vaccination with either dose.
When immunizing the general population with the Pfizer BioNTech
vaccine, anaphylaxis, which is a severe, rapid-onset, multisystem
allergic reaction, was reported in 11.1 cases per 1 million infections [4].
This trend was estimated to be up to ten-fold higher than previous,
commonly used vaccines. When more estimates were generated, and
millions of doses of the COVID-19 vaccines were administered, the
updated anaphylaxis rate was determined to be 4.7 cases per 1 million
doses. Notably, 90% of the anaphylactic reactions were reported among
females, and 81% of the individuals had a history of allergies [4].
Consistent with previous findings, no participants in our study reported
an anaphylactic event at the first dose, and only 0.2% developed it at the
second dose. Coincidentally, the two patients that developed anaphy
laxis were females. In this regard, further studies are needed to accu
rately assess the allergenic components responsible for anaphylaxis so
high-risk patients can be identified and counseled properly to prevent
this type of event.
There are increasing concerns among physicians and patients about
adverse reactions to the COVID-19 vaccines [5]. Given that the vaccine
production is concentrated in the Global North, governments in the
Global South do not have their preference in picking vaccines for the
citizens [6]. Vaccine hesitancy in Latin America is non-uniform, largely
dependent on which vaccine is offered. Data from Latin America sug
gests that citizens may have imprecise beliefs about public health issues,
and the misinformation can lead to hesitancy in acquiring the vaccine
[6]. With few studies conducted in Latin America in this area, we hope
our findings can help to reassure the public that benefits of vaccination
highly outweigh the risks and contribute to the effort of reducing
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